Navigation Links
Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
Date:3/28/2013

product candidate or help fund its development within the U.S.; the potential for significant delays in the development of MST-188, including as a result of delays in the commencement or completion of clinical studies, including due to difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, completing necessary manufacturing process development activities, and being subject to a "clinical hold," or suspension or termination of a clinical study, including due to lack of adequate funding or patient safety concerns; the potential for institutional review boards or the FDA, the EMA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of planned phase 2 clinical studies of MST-188 in any particular indication in which the Company determines to develop MST-188, including acute limb ischemia, which likely would increase the total time and cost of development in the indication; the risk that clinical studies of MST-188 are not successfully executed and/or do not successfully demonstrate its safety or efficacy; the risk that, even if clinical studies are successful, the FDA, the EMA or other regulatory agencies may determine they are not sufficient to support a new drug application; the risk that even if clinical studies of MST-188 in one indication or jurisdiction are successful, clinical studies in another indication or jurisdiction may not be successful; the potential for unsuccessful nonclinical or clinical studies in one indication or jurisdiction, or by a future partner that may be outside of the Company's control, to adversely affect opportunities for MST-188 in other indications or jurisdictions; the Company's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct o
'/>"/>
SOURCE Mast Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Secures $15 Million Loan Financing Agreement
2. United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA
3. DART Therapeutics Develops Drug Candidate for Duchenne Muscular Dystrophy
4. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Research and Markets Announces the Release of Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and Opportunities
6. Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
7. Echo Therapeutics Achieves ISO 13485 Certification
8. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
9. Echo Therapeutics Appoints Robert Doman to Board of Directors
10. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
11. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... Morris , chief financial officer  will be participating in ... as follows: Mizuho Third Annual Healthcare Corporate ... Berkshire Place, New York ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
(Date:4/30/2015)... April 30, 2015   Regulus Therapeutics Inc . ... discovery and development of innovative medicines targeting microRNAs, today ... for the quarter ended March 31, 2015 on Thursday, ... Regulus will host a conference call ... pm Eastern Daylight Time to discuss its first quarter ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... April 14, 2011 Transgenomic, Inc. (OTC/BB: TBIO) announced ... of the BRAF and PIK3CA genes. These ... K-RAS , expanding Transgenomic,s range of its proprietary SURVEYOR Scan ... K-RAS , BRAF , and PIK3CA ) are widely ...
... Nev., April 14, 2011 Sanare, LLC, a ... with diabetes, announced today the launch of its ... BrightSky is the backbone of Sanare,s ... health plans. The offering includes personalized access to ...
Cached Medicine Technology:Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits 2Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits 3Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits 4Sanare Launches BrightSky, a New Consumer Brand Serving People Living With Diabetes 2
(Date:5/3/2015)... 03, 2015 SpineFrontier, a Less Exposure ... FDA to produce and market their new sacroiliac joint ... used in outpatient settings and is compatible with both ... approach has been extensively researched and refined by SpineFrontier, ... use this approach in conjunction with a sacroiliac joint ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... today, Saturday, May 2nd at the MGM Grand Garden Arena ... to secure tickets for both the actual fight and various ... wanted for more than five years was finally been agreed ... inside the ring to fight Manny “Pac-Man” Pacquiao in what ...
(Date:5/2/2015)... May 02, 2015 “ ActOn ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... get connected with organizations to make a difference. , In ... very few things that aren’t about money, which is why ...
(Date:5/2/2015)... NY (PRWEB) May 02, 2015 It’s ... a deadly natural disaster strikes anywhere on this planet, ... leverage human sympathy and compassion for their own personal ... States Computer Emergency Readiness Team) issued an alert ... “of potential email scams citing the earthquake in Nepal. ...
Breaking Medicine News(10 mins):Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4
... When you check into a hospital, the odds are one ... of antibiotic-resistant bacteria as a result of your stay. That ... todays hospitals despite the best efforts of the medical profession. ... deaths per year., Now, a sophisticated new mathematical model has ...
... for,Plastination commends ABC,s 20/20 for its investigation on ... exhibitions. The program served to,inform and educate the ... of bodies used in anatomical exhibitions in particular., ... clarify two vague,statements made by anatomist, Dr. Gunther ...
... survival rates to younger cases , , FRIDAY, Feb. 15 ... transplantation and have good outcomes, and age should not ... a new study says. , Researchers at the University ... of 48 UCLA patients between the ages of 65 ...
... Canadian scientists are finding that out of sight, out of ... the chemicals in our waters. Substances that we use everyday ... they can impact aquatic life and possibly ourselves. , ... of the 30,000 or so chemicals used commercially in the ...
... Premier Exhibitions Inc.,(Nasdaq: PRXI ) today posted ... to an expected 20/20 broadcast that is purported ... to its controversial and,highly successful bodies exhibitions., ... TV,s 20/20 has,chosen to air a segment that ...
... 15 IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced ... by the Company of an additional four million,shares of ... will be made in the open market or in ... shares remaining as of,December 31, 2007, under a previous ...
Cached Medicine News:Health News:Math model identifies key to controlling epidemic 2Health News:Math model identifies key to controlling epidemic 3Health News:Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program 2Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:New findings on emerging contaminants 2Health News:New findings on emerging contaminants 3Health News:New findings on emerging contaminants 4Health News:New findings on emerging contaminants 5Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 2Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 3
Straight shafts with 6 mm tying platform and crisscross serrated tips. Round knurled handle with polished finish. Overall length 4.5 inches....
Curved shafts and tips with 5.5 mm tying platform. 0.3 mm gap at platform heel. True round knurled handle in closed position with polished finish. Overall length 4.3 inches....
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches....
5 mm tying platform. Round knurled handle with dull finish. Straight shafts. Overall length 3.9 inches....
Medicine Products: